WO2026138983 - PHARMACEUTICAL USE OF COMPOUND A OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
National phase entry is expected:
Publication Number
WO/2026/138983
Publication Date
02.07.2026
International Application No.
PCT/CN2025/145713
International Filing Date
25.12.2025
Title **
[English]
PHARMACEUTICAL USE OF COMPOUND A OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
[French]
UTILISATION PHARMACEUTIQUE DU COMPOSÉ A OU D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI
[Chinese]
一种化合物A或其可药用盐的医药用途
Applicants **
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
Inventors
LI, Hongchao
XIAO, Ying
LU, Yinsuo
YANG, Zhao
WU, Jigang
XING, Yan
MU, Shengmei
CHEN, Yan
LAN, Minshi
Priority Data
PCT/CN2024/142727
26.12.2024
CN
202510864538.5
25.06.2025
CN
202510913103.5
02.07.2025
CN
202511374132.5
23.09.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1746 | |
| EPO | Filing, Examination, Granting | 11762 | |
| Japan | Filing, Examination, Granting | 1862 | |
| South Korea | Filing, Examination, Granting | 1519 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,629
Contact Us
Abstract[English]
The present invention belongs to the technical field of chemical drugs. Provided is the pharmaceutical use of compound A or a pharmaceutically acceptable salt thereof. Specifically provided is the use of compound A or a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing or treating diseases associated with hyperaldosteronism.[French]
La présente invention appartient au domaine technique des médicaments chimiques. L'invention concerne l'utilisation pharmaceutique du composé A ou d'un sel pharmaceutiquement acceptable de celui-ci. L'invention concerne plus précisément l'utilisation du composé A ou d'un sel pharmaceutiquement acceptable de celui-ci dans la préparation d'un médicament pour la prévention ou le traitement de maladies associées à l'hyperaldostéronisme.[Chinese]
提供一种化合物A或其可药用盐的医药用途，属于化学药物技术领域，具体提供一种化合物A或其可药用盐在制备用于预防或治疗与醛固酮增多相关疾病的药物中的用途。